// App-Quantinova.ai

POS1057 (2022) : IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS

Researchers

Presenter

  • M. Magrey

Principal Investigators

  • M. Jain

  • R. Ranza

  • J. Stigler

  • E. Mcdearmon-Blondell

  • C. Yue

  • B. Padilla

  • C. Kaufmann

  • D. Mcgonagle

Medical Centers

  • University Hospitals, Rheumatology Division, Cleveland, United States of America

  • Great Lakes Clinical Trials, Chicago, IL, United States of America

  • Federal University of Uberlândia, Rheumatology Unit, Hospital das Clínicas, Uberlândia, Brazil

  • AbbVie Inc, Immunology, Illinois, United States of America

  • University of Washington, Division of Medical Genetics, Seattle, United States of America

  • University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Locations

  • United States

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT03675308

  • NCT03671148

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved